A Phase I, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec (T-VEC) injected into liver tumors

Journal article

Open access

Peer reviewed

J Randolph Hecht, Steven Raman, Daniel Y Sze, A Craig Lockhart, Rebecca A Moss, Kate Liu, Jeffrey Chou and Tony Reid

Journal for immunotherapy of cancer, Vol.3(Suppl 2), pp.P180-P180

2015-11-04

PMCID: PMC4645260

Abstract

Poster Presentation

url

https://doi.org/10.1186/2051-1426-3-S2-P180View

Published (Version of record) Open

11 Record Views

Title: A Phase I, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec (T-VEC) injected into liver tumors
Creators: J Randolph Hecht - David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Steven Raman - David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Daniel Y Sze - Stanford University School of Medicine, Stanford, CA, USA
A Craig Lockhart - Washington University School of Medicine, St. Louis, MO, USA
Rebecca A Moss - Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA
Kate Liu - Amgen Inc., Thousand Oaks, CA, USA
Jeffrey Chou - Amgen Inc., Thousand Oaks, CA, USA
Tony Reid - Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA
Publication Details: Journal for immunotherapy of cancer, Vol.3(Suppl 2), pp.P180-P180
Publisher: BioMed Central
Academic Unit: Miller School of Medicine
Language: English
Resource Type: Journal article
PMCID: PMC4645260
Record Identifier: 991031598689202976